… This was an independent prognostic factor for PFS and overall survival (HR 0.32–0.33)
after adjustment for age, histological diagnosis, focal symptoms at presentation and previous …

… The primary endpoint was overall survival (OS), using an intent-to-treat principle. EudraCT
… in efficacy was observed for temozolomide compared with dacarbazine treatment, our study …

… We therefore chose overall survival as the clinical outcome measure. Investigators in a …
also found overall survival to be a reasonable primary endpoint when the median survival …

… Also regarding overall survival, the number of cycles seems to play a more important role …
treatment in our patient population had no influence on time to progression or overall survival. …

… glioma who had a history of prior treatment with TMZ and were treated with TMZ at the time of
disease … Progression-free survival and overall survival were calculated from the initiation of …

… point was overall survival (OS); secondary end points included progression-free survival (…
In conclusion, treatment with temozolomide has an acceptable safety profile in elderly patients …

… The primary endpoint for this study was overall survival (OS), defined as the time between
the date of resection (or biopsy, if no resection was performed) and death from any cause. The …

… GBM treatment. Recent emerging evidence from clinical trials suggests that a … treatment
of lomustine and TMZ may improve overall survival when used as a first-line treatment for …

… were progression-free survival (PFS) and overall survival (OS) of patients with GBM treated
with TMZ concurrent … A secondary end point was to document the treatment-related toxicity. …

… Our results along with reports elsewhere demonstrated the overall survival benefits associated
with TMZ therapy in patients with GBM. However, there is no uniformity in the treatment …